Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
trading_symbol | registrant_name | time | price | change | percentage_change |
---|---|---|---|---|---|
MRNA | Moderna, Inc. | 2025-10-16 22:04:04 | 27.05 | -0.09 | -0.33 |
trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRNA | 0001682852 | Moderna, Inc. | US60770K1079 | 549300EI6OKH5K5Q2G38 | 813467528 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 325 BINNEY STREET | CAMBRIDGE | MA | 02142 | UNITED STATES | US | 6177146500 | 325 BINNEY STREET, CAMBRIDGE, MA, 02142 | 325 BINNEY STREET, CAMBRIDGE, MA, 02142 | Moderna Therapeutics, Inc. | Biotechnology | 2010 | Stéphane Bancel | 5,800 | http://modernatx.com | 42,100,000,000 | 389,000,000 | 389,079,757 | Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". | 2025-10-10 19:48:48 |
Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
---|---|---|---|---|---|---|
2024 | 42,100,000,000 | 1,900,000,000 | 4.7264 | 385,815,877 | 3,742,669 | 0.9796 |
2023 | 40,200,000,000 | -8,600,000,000 | -17.623 | 382,073,208 | -4,266,386 | -1.1043 |
2022 | 48,800,000,000 | -32,000,000,000 | -39.604 | 386,339,594 | -16,533,392 | -4.1039 |
Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
---|---|---|---|---|---|---|---|---|
Shannon Thyme Klinger | Chief Legal Officer, Corporate Secretary | 2024 | 829,468 | 0 | 11,507,317 | 763,776 | 15,525 | 17,368,701 |
Stephen Hoge | President | 2024 | 1,083,923 | 0 | 4,422,698 | 1,447,992 | 15,525 | 9,181,478 |
Stéphane Bancel | Chief Executive Officer | 2024 | 1,625,885 | 0 | 7,654,730 | 1,965,600 | 975,213 | 19,876,180 |
Arpa Garay | Chief Commercial Officer | 2023 | 842,308 | 0 | 1,460,282 | 619,650 | 63,413 | 4,445,948 |
James Mock | Chief Financial Officer | 2023 | 792,308 | 0 | 1,460,282 | 583,200 | 21,100 | 4,317,185 |
Fiscal Year | Employee Count |
---|---|
2024 | 5,800 |
2023 | 5,600 |
2022 | 3,900 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Revenue | 3,236,000,000 | 6,848,000,000 | 19,263,000,000 |
Cost Of Revenue | 1,464,000,000 | 4,693,000,000 | 5,416,000,000 |
Gross Profit | — | — | — |
Research And Development Expenses | 4,543,000,000 | 4,845,000,000 | 3,295,000,000 |
General And Administrative Expenses | 1,174,000,000 | 1,549,000,000 | 1,132,000,000 |
Operating Expenses | 7,181,000,000 | 11,087,000,000 | 9,843,000,000 |
Operating Income | -3,945,000,000 | -4,239,000,000 | 9,420,000,000 |
Net Income | -3,561,000,000 | -4,714,000,000 | 8,362,000,000 |
Earnings Per Share Basic | -9.28 | -12.33 | 21.26 |
Earnings Per Share Diluted | -9.28 | -12.33 | 20.12 |
Weighted Average Shares Outstanding Basic | 384,000,000 | 382,000,000 | 394,000,000 |
Weighted Average Shares Outstanding Diluted | 384,000,000 | 382,000,000 | 416,000,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Cash And Cash Equivalents | 1,927,000,000 | 2,907,000,000 | 3,205,000,000 |
Marketable Securities Current | 5,098,000,000 | 5,697,000,000 | 6,697,000,000 |
Accounts Receivable | 358,000,000 | 892,000,000 | 1,385,000,000 |
Inventories | 117,000,000 | 202,000,000 | 949,000,000 |
Non Trade Receivables | 72,000,000 | 19,000,000 | 36,000,000 |
Other Assets Current | 58,000,000 | 88,000,000 | 65,000,000 |
Total Assets Current | 8,099,000,000 | 10,325,000,000 | 13,431,000,000 |
Marketable Securities Non Current | 2,494,000,000 | 4,677,000,000 | 8,318,000,000 |
Property Plant And Equipment | — | — | — |
Other Assets Non Current | 594,000,000 | 685,000,000 | 988,000,000 |
Total Assets Non Current | 6,043,000,000 | 8,101,000,000 | 12,427,000,000 |
Total Assets | 14,142,000,000 | 18,426,000,000 | 25,858,000,000 |
Accounts Payable | 405,000,000 | 520,000,000 | 487,000,000 |
Deferred Revenue | 153,000,000 | 568,000,000 | 2,038,000,000 |
Short Term Debt | — | — | — |
Other Liabilities Current | 221,000,000 | 66,000,000 | 249,000,000 |
Total Liabilities Current | 2,206,000,000 | 3,015,000,000 | 4,923,000,000 |
Long Term Debt | — | — | — |
Other Liabilities Non Current | 267,000,000 | 256,000,000 | 135,000,000 |
Total Liabilities Non Current | 1,035,000,000 | 1,557,000,000 | 1,812,000,000 |
Total Liabilities | 3,241,000,000 | 4,572,000,000 | 6,735,000,000 |
Common Stock | 0 | 0 | 0 |
Retained Earnings | 10,045,000,000 | 13,606,000,000 | 18,320,000,000 |
Accumulated Other Comprehensive Income | -10,000,000 | -123,000,000 | -370,000,000 |
Total Shareholders Equity | 10,901,000,000 | 13,854,000,000 | 19,123,000,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Depreciation And Amortization | 185,000,000 | 617,000,000 | 348,000,000 |
Share Based Compensation Expense | 429,000,000 | 305,000,000 | 226,000,000 |
Other Non Cash Income Expense | -60,000,000 | -7,000,000 | -28,000,000 |
Change In Accounts Receivable | -534,000,000 | -493,000,000 | -1,790,000,000 |
Change In Inventories | -83,000,000 | -747,000,000 | -492,000,000 |
Change In Non Trade Receivables | — | — | — |
Change In Other Assets | — | — | — |
Change In Accounts Payable | -69,000,000 | 13,000,000 | 240,000,000 |
Change In Other Liabilities | 78,000,000 | 73,000,000 | 88,000,000 |
Cash From Operating Activities | -3,004,000,000 | -3,118,000,000 | 4,981,000,000 |
Purchases Of Marketable Securities | 6,529,000,000 | 3,760,000,000 | 11,435,000,000 |
Sales Of Marketable Securities | 3,967,000,000 | 3,206,000,000 | 3,548,000,000 |
Acquisition Of Property Plant And Equipment | 1,051,000,000 | 707,000,000 | 400,000,000 |
Acquisition Of Business | 0 | 85,000,000 | — |
Other Investing Activities | — | — | — |
Cash From Investing Activities | 1,949,000,000 | 4,206,000,000 | -5,176,000,000 |
Tax Withholding For Share Based Compensation | — | — | — |
Payments Of Dividends | — | — | — |
Issuance Of Common Stock | 66,000,000 | 46,000,000 | 0 |
Repurchase Of Common Stock | 0 | 1,153,000,000 | 3,329,000,000 |
Issuance Of Long Term Debt | — | — | — |
Repayment Of Long Term Debt | — | — | — |
Other Financing Activities | — | — | — |
Cash From Financing Activities | 56,000,000 | -1,377,000,000 | -3,448,000,000 |
Change In Cash | -999,000,000 | -289,000,000 | -3,643,000,000 |
Cash At End Of Period | 1,927,000,000 | 2,907,000,000 | 3,205,000,000 |
Income Taxes Paid | 197,000,000 | -357,000,000 | 2,729,000,000 |
Interest Paid | 24,000,000 | 39,000,000 | 25,000,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Earnings Per Share | -9.28 | -12.33 | 21.26 |
Price To Earnings Ratio | -4.4806 | -8.0657 | 8.4487 |
Earnings Growth Rate | -24.7364 | -157.9962 | -29.8581 |
Price Earnings To Growth Ratio | 0.1811 | 0.051 | -0.283 |
Book Value Per Share | 28.388 | 36.267 | 48.5355 |
Price To Book Ratio | 1.4647 | 2.7422 | 3.7008 |
Ebitda | -3,179,000,000 | -4,454,000,000 | 11,439,000,000 |
Enterprise Value | — | — | — |
Dividend Yield | — | — | — |
Dividend Payout Ratio | — | — | — |
Debt To Equity Ratio | — | — | — |
Capital Expenditures | — | — | — |
Free Cash Flow | — | — | — |
Return On Equity | -0.3267 | -0.3403 | 0.4373 |
One Year Beta | 1.4597 | 1.0272 | 1.5679 |
Three Year Beta | 1.4192 | 1.2162 | 0.5347 |
Five Year Beta | 0.6281 | 0.6204 | 0.6016 |
Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
---|---|---|---|---|---|
Mock James M | Chief Financial Officer | 2025-10-03 | 1,453 | A | 18,962 |
Mock James M | Chief Financial Officer | 2025-10-03 | 703 | D | 18,259 |
Mock James M | Chief Financial Officer | 2025-10-03 | 1,453 | D | 5,811 |
Hussain Abbas | Director | 2025-10-02 | 1,439 | A | 2,019 |
Hussain Abbas | Director | 2025-10-02 | 1,439 | D | 0 |
Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
---|---|---|---|---|---|---|
Rob Bresnahan | 2025-05-08 | PA08 | Sale | 2025-04-08 | — | $1,001 - $15,000 |
Rob Bresnahan | 2025-03-27 | PA08 | Purchase | 2025-02-25 | — | $1,001 - $15,000 |
Julie Johnson | 2025-02-12 | TX32 | Sale | 2025-01-15 | Joint | $1,001 - $15,000 |
Josh Gottheimer | 2024-03-07 | NJ05 | Sale | 2024-02-01 | Joint | $1,001 - $15,000 |
Josh Gottheimer | 2023-10-15 | NJ05 | Sale | 2023-09-15 | Joint | $1,001 - $15,000 |
Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
---|---|---|---|---|
180 WEALTH ADVISORS, LLC | 2025-09-30 | 703,919 | 27,252 | 25.83 |
Lowe Wealth Advisors, LLC | 2025-09-30 | 3,358 | 130 | 25.8308 |
Capital Advisors, Ltd. LLC | 2025-09-30 | 1,000 | 21 | 47.619 |
Signature Resources Capital Management, LLC | 2025-09-30 | 827 | 32 | 25.8438 |
PFS Partners, LLC | 2025-09-30 | 282 | 11 | 25.6364 |
Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
---|---|---|---|---|---|---|
TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Mid Cap Fund | CFMCX | 3,046 | 73,378.14 | 0.0074 |
ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 1,399 | 41,354.44 | 0.0173 |
Pacer Funds Trust | 2025-07-31 | Pacer Trendpilot US Large Cap ETF | PTLC | 21,036 | 621,824.16 | 0.0186 |
Pacer Funds Trust | 2025-07-31 | Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF | QDPL | 6,184 | 182,799.04 | 0.0168 |
Pacer Funds Trust | 2025-07-31 | Pacer CFRA-Stovall Equal Weight Seasonal Rotation ETF | SZNE | 4,719 | 139,493.64 | 0.9171 |